Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15055670 | 0.82 | KDM4E (0.35) | KDM4EKMT2AOPRM1CYP4F2CYP4A11 | |
| SCHEMBL28487708 | 0.78 | KDM4E (0.33) | KDM4EKMT2AOPRM1CYP4F2CYP4A11 | |
| SCHEMBL4372862 | 0.78 | FFAR3 (0.34) | KDM4EKMT2AOPRM1CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL23211002 | 0.77 | FFAR3 (0.33) | KDM4EKMT2AOPRM1CYP4F2CYP4A11 | |
| SCHEMBL2146137 | 0.77 | OPRM1 (0.34) | KDM4EKMT2AOPRM1CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL6643227 | 0.77 | KDM4E (0.32) | KDM4EKMT2AOPRM1CYP4F2CYP4A11 | |
| SCHEMBL984738 | 0.77 | KDM4E (0.36) | KDM4EKMT2AOPRM1CYP4F2CYP4A11 | |
| SCHEMBL27426214 | 0.77 | KDM4E (0.32) | KDM4EKMT2AOPRM1CYP4F2CYP4A11 | |
| SCHEMBL13362182 | 0.76 | KDM4E (0.32) | KDM4EKMT2AOPRM1 | |
| SCHEMBL6371579 | 0.76 | KDM4E (0.32) | KDM4EKMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2024334-A2 | SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007136607-A2 | SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | KDM4E 2066/4885KMT2A 2455/4885OPRM1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.